Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression.
Adult
Antigens, CD34
/ biosynthesis
Cell Line, Tumor
/ metabolism
Chromosome Deletion
Chromosome Inversion
Chromosomes, Human, Pair 3
/ genetics
Chromosomes, Human, Pair 7
/ genetics
Coculture Techniques
Gene Expression Regulation, Leukemic
Humans
Leukemia, Myeloid, Acute
/ genetics
Male
Neoplasm Proteins
/ biosynthesis
Stromal Cells
/ metabolism
Journal
Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
29
08
2018
revised:
12
10
2018
accepted:
15
10
2018
pubmed:
24
10
2018
medline:
27
3
2019
entrez:
24
10
2018
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.
Identifiants
pubmed: 30352278
pii: S0301-472X(18)30868-3
doi: 10.1016/j.exphem.2018.10.006
pii:
doi:
Substances chimiques
Antigens, CD34
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-36Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2018. Published by Elsevier Inc.